\-\ Texto\\:\\ \ \(0\)\
\-\ right\\ eye\\ proptosis\ \(2\)\
\-\ children\\ with\\ nf1\\ should\\ be\\ monitored\\ for\\ developmental\\ progress\\ and\\ should\\ be\\ seen\\ yearly\\ for\\ neurological\\ exams\\.\\ more\\ about\\ general\\ treatment\\ for\\ nf1\\ patients\\ will\\ be\\ discussed\\ in\\ the\\ discussion\\.\\ \\ as\\ for\\ her\\ specific\\ findings\\ on\\ this\\ ct\\ study\\,\\ treatment\\ and\\ follow\\-up\\ are\\ as\\ follows\\:\ \(0\)\
\-\ plexiform\\ neurofibroma\\:\\ \\ lesions\\ usually\\ involve\\ multiple\\ nerve\\ fascicles\\ with\\ significant\\ vascularity\\.\\ thus\\,\\ surgical\\ excision\\ is\\ generally\\ difficult\\ and\\ frustrating\\,\\ with\\ excessive\\ bleeding\\ and\\ a\\ poor\\ cosmetic\\ result\\.\\ repeated\\ debulking\\ may\\ be\\ necessary\\ for\\ severe\\ symptoms\\,\\ and\\ orbital\\ evisceration\\ for\\ extensive\\ cases\\.\\ radiotherapy\\ offers\\ no\\ benefit\\.\\ however\\,\\ farnesyl\\ transferase\\ inhibitors\\,\\ which\\ inhibit\\ growth\\ of\\ these\\ tumors\\ in\\ animals\\,\\ are\\ a\\ possible\\ treatment\\ in\\ the\\ future\\ and\\ are\\ currently\\ undergoing\\ clinical\\ trials\\.\\ \\ of\\ concern\\,\\ there\\ is\\ a\\ small\\ risk\\ of\\ malignant\\ transformation\\ of\\ these\\ tumors\\.\\ they\\ may\\ occasionally\\ erode\\ into\\ the\\ anterior\\ cranial\\ fossa\\,\\ which\\ results\\ in\\ death\\.\ \(0\)\
\-\ optic\\ nerve\\ glioma\\:\\ \\ the\\ radiologist\\ of\\ this\\ case\\ recommended\\ further\\ evaluation\\ with\\ mri\\ of\\ the\\ brain\\ and\\ orbits\\.\\ if\\ the\\ mri\\ is\\ positive\\ for\\ an\\ optic\\ nerve\\ glioma\\,\\ mri\\ and\\ an\\ ophthalmic\\ exam\\ are\\ repeated\\ every\\ 3\\-6\\ months\\.\\ otherwise\\,\\ if\\ vision\\ is\\ ok\\,\\ observation\\ is\\ the\\ treatment\\.\\ if\\ the\\ tumor\\ progresses\\,\\ the\\ child\\ should\\ be\\ referred\\ to\\ neurooncology\\ for\\ evaluation\\.\\ \\ surgical\\ excision\\ is\\ offered\\ if\\ a\\ tumor\\ approaches\\ the\\ chiasm\\.\\ surgery\\ also\\ is\\ indicated\\ for\\ pain\\ or\\ disfiguring\\ proptosis\\.\\ the\\ role\\ of\\ radiotherapy\\ remains\\ controversial\\;\\ it\\ may\\ be\\ associated\\ with\\ cns\\ complications\\.\\ more\\ recently\\,\\ chemotherapy\\ has\\ shown\\ promising\\ results\\.\ \(0\)\
\-\ \\â\\€\\¢\\	a\\ soft\\ tissue\\ mass\\ noted\\ laterally\\ to\\ the\\ lateral\\ rectus\\ muscle\\ in\\ the\\ pre\\ and\\ post\\ septal\\ portions\\ of\\ the\\ right\\ orbit\\ \ \(0\)\
\-\ \\â\\€\\¢\\	asymmetry\\ of\\ the\\ csf\\-containing\\ spaces\\ in\\ the\\ middle\\ cranial\\ fossa\\,\\ larger\\ on\\ the\\ right\\ without\\ mass\\ effect\\ on\\ the\\ temporal\\ lobe\\.\ \(0\)\
\-\ \\â\\€\\¢\\	right\\ sphenoid\\ wing\\ hypoplasia\\ causing\\ deformity\\ of\\ the\\ right\\ orbit\\,\\ which\\ is\\ widened\\ and\\ flattened\\ posteriorly\\ rather\\ than\\ conical\\.\ \(0\)\
\-\ \\â\\€\\¢\\	right\\ optic\\ nerve\\ has\\ a\\ globular\\ appearance\\ near\\ the\\ orbital\\ fissure\ \(0\)\
\-\ \\â\\€\\¢\\	unenhanced\\ brain\\ parenchyma\\ demonstrates\\ no\\ abnormality\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\	globes\\ are\\ symmetrical\\ in\\ size\\ and\\ appearance\ \(0\)\
\-\ \\â\\€\\¢\\	left\\ optic\\ nerve\\ is\\ unremarkable\ \(0\)\
\-\ neurofibromatosis\\ type\\ 1\\ \\(nf1\\)\\,\\ right\\ orbital\\ plexiform\\ neurofibroma\\,\\ sphenoid\\ wing\\ hypoplasia\\,\\ possible\\ optic\\ nerve\\ glioma\\.\ \(0\)\
\-\ soft\\ tissue\\ mass\ \(178\)\
\-\ \\â\\€\\¢\\	plexiform\\ neurofibroma\\ of\\ the\\ orbit\ \(0\)\
\-\ \\â\\€\\¢\\	dermoid\\ cyst\ \(0\)\
\-\ \\â\\€\\¢\\	infectious\\ \\(lacrimal\\ gland\\,\\ orbital\\ cellulitis\\)\ \(0\)\
\-\ \\â\\€\\¢\\	other\\ sarcoma\\ \\(i\\.e\\.\\ rhabdomyosarcoma\\,\\ lipoma\\)\ \(0\)\
\-\ \\â\\€\\¢\\	lymphoma\ \(0\)\
\-\ right\\ middle\\ fossa\\ fluid\ \(0\)\
\-\ \\â\\€\\¢\\	epidermoid\\ cyst\ \(0\)\
\-\ \\â\\€\\¢\\	arachnoid\\ cyst\ \(0\)\
\-\ sphenoid\\ wing\\ hypoplasia\ \(2\)\
\-\ \\â\\€\\¢\\	bone\\ dysplasia\\ secondary\\ to\\ plexiform\\ neurofibroma\ \(0\)\
\-\ \\â\\€\\¢\\	congenital\\ bony\\ malformation\ \(0\)\
\-\ \\â\\€\\¢\\	trauma\ \(0\)\
\-\ right\\ optic\\ nerve\\ globular\\ appearance\ \(0\)\
\-\ \\â\\€\\¢\\	optic\\ nerve\\ glioma\ \(0\)\
\-\ \\â\\€\\¢\\	suprasellar\\ germinoma\ \(0\)\
\-\ \\â\\€\\¢\\	craniopharyngioma\ \(0\)\
\-\ \\â\\€\\¢\\	infiltrative\\ disorders\\ such\\ as\\ sarcoidosis\\,\\ lymphoma\\,\\ and\\ langerhans\\ histiocytosis\\.\ \(0\)\
\-\ 21\\ month\\ old\\ girl\\ with\\ proptosis\ \(1\)\
\-\ our\\ patient\\ has\\ been\\ given\\ the\\ definitive\\ diagnosis\\ of\\ nf1\\ because\\ of\\ the\\ plexiform\\ neurofibroma\\ and\\ sphenoid\\ hypoplasia\\.\\ \\ it\\ is\\ a\\ likely\\ assumption\\ that\\ the\\ optic\\ nerve\\ mass\\ is\\ an\\ optic\\ nerve\\ glioma\\ given\\ this\\ patient\\â\\€\\™s\\ diagnosis\\ of\\ nf1\\.\\ \\ follow\\-up\\ mri\\ should\\ reveal\\ a\\ hypotense\\ to\\ isotense\\ t1\\ signal\\ and\\ variable\\ intensity\\ compared\\ to\\ muscle\\ on\\ t2\\ weighted\\ imaging\\.\\ \\ enhancement\\ with\\ gadolinium\\ is\\ also\\ variable\\.\\ typically\\,\\ the\\ lesion\\ appears\\ as\\ a\\ fusiform\\ enlargement\\ of\\ the\\ optic\\ nerve\\,\\ possibly\\ involving\\ the\\ optic\\ chiasm\\.\\ the\\ nerve\\ may\\ appear\\ kinked\\ with\\ cystic\\ spaces\\.\ \(0\)\
\-\ if\\ no\\ potential\\ problem\\ develops\\,\\ this\\ 2\\ year\\ old\\ needs\\ yearly\\ medical\\ visits\\ to\\ include\\ physical\\ exam\\,\\ ophthalmologic\\ exam\\,\\ growth\\ measurements\\,\\ assessment\\ for\\ precocious\\ puberty\\,\\ developmental\\ assessment\\,\\ and\\ review\\ of\\ educational\\ progress\\.\\ also\\,\\ as\\ previously\\ mentioned\\,\\ because\\ of\\ her\\ tumors\\,\\ she\\ would\\ need\\ a\\ follow\\-up\\ mri\\ every\\ 3\\-6\\ months\\.\\ \\ obviously\\,\\ this\\ management\\ involves\\ a\\ multidisciplinary\\ team\\ involving\\ genetics\\,\\ neurology\\,\\ ophthalmology\\,\\ dermatology\\,\\ neurosurgery\\,\\ and\\ plastic\\ surgery\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ optic\\:\\ 0\\.06427291907777412\ \(0\)\
\-\ nerve\\:\\ 0\\.054575115979095534\ \(0\)\
\-\ plexiform\\:\\ 0\\.04887957050687059\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.048607535278454427\ \(0\)\
\-\ nf1\\:\\ 0\\.044182459969795286\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.03499247400340309\ \(0\)\
\-\ glioma\\:\\ 0\\.028454016201673493\ \(0\)\
\-\ sphenoid\\:\\ 0\\.028094980286086143\ \(0\)\
\-\ hypoplasia\\:\\ 0\\.027513355040513006\ \(0\)\
\-\ orbital\\:\\ 0\\.023948859611041314\ \(0\)\
\-\ wing\\:\\ 0\\.02384725798883908\ \(0\)\
\-\ proptosis\\:\\ 0\\.021148303498369048\ \(0\)\
\-\ globular\\:\\ 0\\.01989978399493844\ \(0\)\
\-\ orbit\\:\\ 0\\.01907529800937806\ \(0\)\
\-\ 3\\-6\\:\\ 0\\.017504126044520927\ \(0\)\
\-\ if\\:\\ 0\\.017125136143136155\ \(0\)\
\-\ yearly\\:\\ 0\\.017048732603376884\ \(0\)\
\-\ should\\:\\ 0\\.01609576686492644\ \(0\)\
\-\ \\,\\:\\ 0\\.015994686293488176\ \(0\)\
\-\ fossa\\:\\ 0\\.015433380933682996\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.015375481569637441\ \(0\)\
\-\ chiasm\\:\\ 0\\.01500103044514957\ \(0\)\
\-\ repeated\\:\\ 0\\.01460655070327506\ \(0\)\
\-\ mri\\:\\ 0\\.014499821675883455\ \(0\)\
\-\ progress\\:\\ 0\\.014258594911084856\ \(0\)\
\-\ tumors\\:\\ 0\\.0142232630325133\ \(0\)\
\-\ assessment\\:\\ 0\\.01357757967146349\ \(0\)\
\-\ variable\\:\\ 0\\.013450040020458444\ \(0\)\
\-\ every\\:\\ 0\\.013408721728066302\ \(0\)\
\-\ frustrating\\:\\ 0\\.01302144523481019\ \(0\)\
\-\ farnesyl\\:\\ 0\\.01302144523481019\ \(0\)\
\-\ transferase\\:\\ 0\\.01302144523481019\ \(0\)\
\-\ animals\\:\\ 0\\.01302144523481019\ \(0\)\
\-\ neurooncology\\:\\ 0\\.01302144523481019\ \(0\)\
\-\ disfiguring\\:\\ 0\\.01302144523481019\ \(0\)\
\-\ hypotense\\:\\ 0\\.01302144523481019\ \(0\)\
\-\ isotense\\:\\ 0\\.01302144523481019\ \(0\)\
\-\ educational\\:\\ 0\\.01302144523481019\ \(0\)\
\-\ spaces\\:\\ 0\\.012438251810866786\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.012319218573597085\ \(0\)\
\-\ right\\:\\ 0\\.011986241332339364\ \(0\)\
\-\ developmental\\:\\ 0\\.011732145753346846\ \(0\)\
\-\ be\\:\\ 0\\.011678789276312518\ \(0\)\
\-\ evisceration\\:\\ 0\\.011398679668092155\ \(0\)\
\-\ inhibit\\:\\ 0\\.011398679668092155\ \(0\)\
\-\ ok\\:\\ 0\\.011398679668092155\ \(0\)\
\-\ promising\\:\\ 0\\.011398679668092155\ \(0\)\
\-\ assumption\\:\\ 0\\.011398679668092155\ \(0\)\
\-\ kinked\\:\\ 0\\.011398679668092155\ \(0\)\
\-\ may\\:\\ 0\\.011074318280048\ \(0\)\
\-\ growth\\:\\ 0\\.010976815350494239\ \(0\)\
\-\ cranial\\:\\ 0\\.010976815350494239\ \(0\)\
\-\ fascicles\\:\\ 0\\.010973743076582878\ \(0\)\
\-\ erode\\:\\ 0\\.010973743076582878\ \(0\)\
\-\ conical\\:\\ 0\\.010973743076582878\ \(0\)\
\-\ appearance\\:\\ 0\\.010829718951556757\ \(0\)\
\-\ for\\:\\ 0\\.010769692003585156\ \(0\)\
\-\ offers\\:\\ 0\\.010374828588978499\ \(0\)\
\-\ multidisciplinary\\:\\ 0\\.010374828588978499\ \(0\)\
\-\ excision\\:\\ 0\\.010361154288228341\ \(0\)\
\-\ treatment\\:\\ 0\\.010219302567804355\ \(0\)\
\-\ results\\:\\ 0\\.01019067181372126\ \(0\)\
\-\ cyst\\:\\ 0\\.010175942995684355\ \(0\)\
\-\ csf\\-containing\\:\\ 0\\.010147131868406477\ \(0\)\
\-\ is\\:\\ 0\\.009966749395297944\ \(0\)\
\-\ ophthalmologic\\:\\ 0\\.00994989199746922\ \(0\)\
\-\ obviously\\:\\ 0\\.00994989199746922\ \(0\)\
\-\ globes\\:\\ 0\\.00977591410137412\ \(0\)\
\-\ precocious\\:\\ 0\\.00977591410137412\ \(0\)\
\-\ approaches\\:\\ 0\\.009620285570121791\ \(0\)\
\-\ as\\:\\ 0\\.0095463626727779\ \(0\)\
\-\ inhibitors\\:\\ 0\\.009350977509864841\ \(0\)\
\-\ cosmetic\\:\\ 0\\.009232746036196398\ \(0\)\
\-\ middle\\:\\ 0\\.009232375094955503\ \(0\)\
\-\ trials\\:\\ 0\\.009123280789292821\ \(0\)\
\-\ muscle\\:\\ 0\\.009067400985011359\ \(0\)\
\-\ flattened\\:\\ 0\\.009021371082517413\ \(0\)\
\-\ visits\\:\\ 0\\.009021371082517413\ \(0\)\
\-\ puberty\\:\\ 0\\.009021371082517413\ \(0\)\
\-\ genetics\\:\\ 0\\.009021371082517413\ \(0\)\
\-\ debulking\\:\\ 0\\.008926040918355565\ \(0\)\
\-\ germinoma\\:\\ 0\\.008926040918355565\ \(0\)\
\-\ involving\\:\\ 0\\.008857923970467634\ \(0\)\
\-\ because\\:\\ 0\\.008831664155350217\ \(0\)\
\-\ plastic\\:\\ 0\\.008672200066174385\ \(0\)\
\-\ given\\:\\ 0\\.008654104556916817\ \(0\)\
\-\ are\\:\\ 0\\.008603204376141814\ \(0\)\
\-\ ophthalmic\\:\\ 0\\.008596434491008135\ \(0\)\
\-\ offered\\:\\ 0\\.008596434491008135\ \(0\)\
\-\ lacrimal\\:\\ 0\\.008596434491008135\ \(0\)\
\-\ ophthalmology\\:\\ 0\\.008524366301688442\ \(0\)\
\-\ possible\\:\\ 0\\.008502163128165648\ \(0\)\
\-\ progresses\\:\\ 0\\.008455651359834834\ \(0\)\
\-\ measurements\\:\\ 0\\.008389991444663736\ \(0\)\
\-\ pre\\:\\ 0\\.008327126430751185\ \(0\)\
\-\ exam\\:\\ 0\\.008318614209525281\ \(0\)\
\-\ controversial\\:\\ 0\\.008266828063660706\ \(0\)\
\-\ orbits\\:\\ 0\\.008208894957082742\ \(0\)\
\-\ symmetrical\\:\\ 0\\.008153148534656086\ \(0\)\
\-\ needs\\:\\ 0\\.007997520003403756\ \(0\)\
\-\ asymmetry\\:\\ 0\\.007902189839241907\ \(0\)\
\-\ unenhanced\\:\\ 0\\.007769823282831735\ \(0\)\
\-\ neurology\\:\\ 0\\.007687740784818721\ \(0\)\
\-\ excessive\\:\\ 0\\.007648348987060728\ \(0\)\
\-\ fusiform\\:\\ 0\\.007648348987060728\ \(0\)\
\-\ develops\\:\\ 0\\.007648348987060728\ \(0\)\
\-\ monitored\\:\\ 0\\.007609980469478364\ \(0\)\
\-\ brain\\:\\ 0\\.007596311737969755\ \(0\)\
\-\ her\\:\\ 0\\.007590580970413399\ \(0\)\
\-\ team\\:\\ 0\\.0075725834118944785\ \(0\)\
\-\ benefit\\:\\ 0\\.007536109833474433\ \(0\)\
\-\ mentioned\\:\\ 0\\.007536109833474433\ \(0\)\
\-\ widened\\:\\ 0\\.007500515222574785\ \(0\)\
\-\ cellulitis\\:\\ 0\\.007500515222574785\ \(0\)\
\-\ role\\:\\ 0\\.007465758210152047\ \(0\)\
\-\ langerhans\\:\\ 0\\.007465758210152047\ \(0\)\
\-\ also\\:\\ 0\\.007465079440192695\ \(0\)\
\-\ evaluation\\:\\ 0\\.00733305404970992\ \(0\)\
\-\ rectus\\:\\ 0\\.00730327535163753\ \(0\)\
\-\ radiologist\\:\\ 0\\.007242976984547049\ \(0\)\
\-\ infiltrative\\:\\ 0\\.007242976984547049\ \(0\)\
\-\ lymphoma\\:\\ 0\\.007214767014444567\ \(0\)\
\-\ transformation\\:\\ 0\\.007156907696328475\ \(0\)\
\-\ exams\\:\\ 0\\.007129297455542428\ \(0\)\
\-\ has\\:\\ 0\\.0071109304453217635\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.007102193853373748\ \(0\)\
\-\ neurosurgery\\:\\ 0\\.007102193853373748\ \(0\)\
\-\ this\\:\\ 0\\.007098502313989165\ \(0\)\
\-\ laterally\\:\\ 0\\.007075578631065508\ \(0\)\
\-\ which\\:\\ 0\\.007068587535786775\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.007023745071521536\ \(0\)\
\-\ mass\\:\\ 0\\.0070219261858054036\ \(0\)\
\-\ future\\:\\ 0\\.006998494800680619\ \(0\)\
\-\ vascularity\\:\\ 0\\.006973668924290101\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.006973668924290101\ \(0\)\
\-\ discussed\\:\\ 0\\.006901600734970407\ \(0\)\
\-\ problem\\:\\ 0\\.006901600734970407\ \(0\)\
\-\ months\\:\\ 0\\.0068949521261154135\ \(0\)\
\-\ septal\\:\\ 0\\.0068783387601282515\ \(0\)\
\-\ suprasellar\\:\\ 0\\.0068783387601282515\ \(0\)\
\-\ death\\:\\ 0\\.006810673271160314\ \(0\)\
\-\ dermatology\\:\\ 0\\.006810673271160314\ \(0\)\
\-\ follows\\:\\ 0\\.006788789835731745\ \(0\)\
\-\ fissure\\:\\ 0\\.0067672258779457005\ \(0\)\
\-\ i\\.e\\:\\ 0\\.006745972203718078\ \(0\)\
\-\ craniopharyngioma\\:\\ 0\\.006683986680676673\ \(0\)\
\-\ occasionally\\:\\ 0\\.006644062496942671\ \(0\)\
\-\ these\\:\\ 0\\.0065697036690039595\ \(0\)\
\-\ remains\\:\\ 0\\.0065673125132931715\ \(0\)\
\-\ portions\\:\\ 0\\.0065673125132931715\ \(0\)\
\-\ observation\\:\\ 0\\.006476664143461129\ \(0\)\
\-\ cns\\:\\ 0\\.006459183408384316\ \(0\)\
\-\ possibly\\:\\ 0\\.006459183408384316\ \(0\)\
\-\ a\\:\\ 0\\.006444014505176681\ \(0\)\
\-\ arachnoid\\:\\ 0\\.006342289286436422\ \(0\)\
\-\ more\\:\\ 0\\.006313667088071392\ \(0\)\
\-\ need\\:\\ 0\\.006294891480599642\ \(0\)\
\-\ thus\\:\\ 0\\.006279424272523874\ \(0\)\
\-\ concern\\:\\ 0\\.006279424272523874\ \(0\)\
\-\ definitive\\:\\ 0\\.0062339713055124205\ \(0\)\
\-\ undergoing\\:\\ 0\\.006189875348127366\ \(0\)\
\-\ soft\\:\\ 0\\.006147494132920385\ \(0\)\
\-\ surgery\\:\\ 0\\.006129982464875259\ \(0\)\
\-\ larger\\:\\ 0\\.006078342774260091\ \(0\)\
\-\ potential\\:\\ 0\\.006078342774260091\ \(0\)\
\-\ disorders\\:\\ 0\\.006038597644393143\ \(0\)\
\-\ epidermoid\\:\\ 0\\.006012682859088994\ \(0\)\
\-\ rather\\:\\ 0\\.005999893992407879\ \(0\)\
\-\ our\\:\\ 0\\.005999893992407879\ \(0\)\
\-\ gadolinium\\:\\ 0\\.0059872149027603285\ \(0\)\
\-\ tissue\\:\\ 0\\.0059835190205394205\ \(0\)\
\-\ posteriorly\\:\\ 0\\.005962178627555346\ \(0\)\
\-\ involve\\:\\ 0\\.005949817845176444\ \(0\)\
\-\ discussion\\:\\ 0\\.0059133442667563966\ \(0\)\
\-\ lipoma\\:\\ 0\\.005901383838052381\ \(0\)\
\-\ recently\\:\\ 0\\.005889519478085964\ \(0\)\
\-\ tumor\\:\\ 0\\.005885472087476548\ \(0\)\
\-\ involves\\:\\ 0\\.005866072876673423\ \(0\)\
\-\ vision\\:\\ 0\\.005831586371508\ \(0\)\
\-\ diagnosis\\:\\ 0\\.005796807476456189\ \(0\)\
\-\ dermoid\\:\\ 0\\.005754117427087701\ \(0\)\
\-\ the\\:\\ 0\\.00571784338508349\ \(0\)\
\-\ 21\\:\\ 0\\.005711607878269321\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.005701168931115565\ \(0\)\
\-\ generally\\:\\ 0\\.005680509784919494\ \(0\)\
\-\ poor\\:\\ 0\\.005680509784919494\ \(0\)\
\-\ it\\:\\ 0\\.0056745890237312165\ \(0\)\
\-\ sarcoma\\:\\ 0\\.005620211417829014\ \(0\)\
\-\ reveal\\:\\ 0\\.005620211417829014\ \(0\)\
\-\ necessary\\:\\ 0\\.005590960860522988\ \(0\)\
\-\ difficult\\:\\ 0\\.005524881253667166\ \(0\)\
\-\ child\\:\\ 0\\.005524881253667166\ \(0\)\
\-\ weighted\\:\\ 0\\.005488407675247119\ \(0\)\
\-\ bleeding\\:\\ 0\\.005479428286655713\ \(0\)\
\-\ review\\:\\ 0\\.005470503154519875\ \(0\)\
\-\ neurological\\:\\ 0\\.005461631627104496\ \(0\)\
\-\ indicated\\:\\ 0\\.005461631627104496\ \(0\)\
\-\ near\\:\\ 0\\.005461631627104496\ \(0\)\
\-\ children\\:\\ 0\\.0054528130643474735\ \(0\)\
\-\ causing\\:\\ 0\\.0054528130643474735\ \(0\)\
\-\ deformity\\:\\ 0\\.0054353323292706595\ \(0\)\
\-\ infectious\\:\\ 0\\.005426668932738314\ \(0\)\
\-\ parenchyma\\:\\ 0\\.005375729233962584\ \(0\)\
\-\ gland\\:\\ 0\\.005375729233962584\ \(0\)\
\-\ compared\\:\\ 0\\.0053427199301339335\ \(0\)\
\-\ general\\:\\ 0\\.005318438207322767\ \(0\)\
\-\ surgical\\:\\ 0\\.005306415864849198\ \(0\)\
\-\ previously\\:\\ 0\\.005302469350448002\ \(0\)\
\-\ eye\\:\\ 0\\.005294549198097359\ \(0\)\
\-\ an\\:\\ 0\\.00523632879298994\ \(0\)\
\-\ recommended\\:\\ 0\\.005232671883903622\ \(0\)\
\-\ specific\\:\\ 0\\.005217599254399572\ \(0\)\
\-\ appear\\:\\ 0\\.005166024269013711\ \(0\)\
\-\ shown\\:\\ 0\\.005061221113958637\ \(0\)\
\-\ temporal\\:\\ 0\\.005054491695146436\ \(0\)\
\-\ extensive\\:\\ 0\\.005047792795345267\ \(0\)\
\-\ bony\\:\\ 0\\.005047792795345267\ \(0\)\
\-\ malformation\\:\\ 0\\.005034485454219173\ \(0\)\
\-\ \\:\\:\\ 0\\.0050086033204903915\ \(0\)\
\-\ enlargement\\:\\ 0\\.005008225120362032\ \(0\)\
\-\ currently\\:\\ 0\\.005001732341229036\ \(0\)\
\-\ complications\\:\\ 0\\.005001732341229036\ \(0\)\
\-\ dysplasia\\:\\ 0\\.004982423505826743\ \(0\)\
\-\ about\\:\\ 0\\.0048656683989723075\ \(0\)\
\-\ result\\:\\ 0\\.004842221797559766\ \(0\)\
\-\ referred\\:\\ 0\\.004762971112933001\ \(0\)\
\-\ management\\:\\ 0\\.004762971112933001\ \(0\)\
\-\ appears\\:\\ 0\\.004698270045490767\ \(0\)\
\-\ abnormality\\:\\ 0\\.004656658705805838\ \(0\)\
\-\ congenital\\:\\ 0\\.004616187547477751\ \(0\)\
\-\ risk\\:\\ 0\\.004571944826232034\ \(0\)\
\-\ malignant\\:\\ 0\\.0045622905116385545\ \(0\)\
\-\ intensity\\:\\ 0\\.0045622905116385545\ \(0\)\
\-\ they\\:\\ 0\\.004547926331591294\ \(0\)\
\-\ otherwise\\:\\ 0\\.004533700492505679\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.004524292149395665\ \(0\)\
\-\ would\\:\\ 0\\.004491826999146366\ \(0\)\
\-\ effect\\:\\ 0\\.004469066843529166\ \(0\)\
\-\ typically\\:\\ 0\\.004455577207542057\ \(0\)\
\-\ girl\\:\\ 0\\.004437780547990839\ \(0\)\
\-\ in\\:\\ 0\\.004357135319027747\ \(0\)\
\-\ on\\:\\ 0\\.004277051771730742\ \(0\)\
\-\ type\\:\\ 0\\.004254984089138715\ \(0\)\
\-\ and\\:\\ 0\\.0042542748769800525\ \(0\)\
\-\ size\\:\\ 0\\.00423172211429656\ \(0\)\
\-\ cases\\:\\ 0\\.004205038203812603\ \(0\)\
\-\ unremarkable\\:\\ 0\\.004178827797167003\ \(0\)\
\-\ study\\:\\ 0\\.004153074382363307\ \(0\)\
\-\ positive\\:\\ 0\\.0040958428216899805\ \(0\)\
\-\ further\\:\\ 0\\.004013949987888121\ \(0\)\
\-\ t1\\:\\ 0\\.004000731958972295\ \(0\)\
\-\ post\\:\\ 0\\.003974645543681379\ \(0\)\
\-\ will\\:\\ 0\\.003949011843986916\ \(0\)\
\-\ such\\:\\ 0\\.003945838685141584\ \(0\)\
\-\ severe\\:\\ 0\\.003883766322106358\ \(0\)\
\-\ clinical\\:\\ 0\\.003883766322106358\ \(0\)\
\-\ medical\\:\\ 0\\.003883766322106358\ \(0\)\
\-\ usually\\:\\ 0\\.00383298117262446\ \(0\)\
\-\ no\\:\\ 0\\.003812898747579625\ \(0\)\
\-\ month\\:\\ 0\\.003786727534417444\ \(0\)\
\-\ to\\:\\ 0\\.0037849463082096275\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.003772565346595947\ \(0\)\
\-\ cystic\\:\\ 0\\.0036405209856008253\ \(0\)\
\-\ s\\:\\ 0\\.0036200408672298185\ \(0\)\
\-\ fluid\\:\\ 0\\.0035873546596807285\ \(0\)\
\-\ t2\\:\\ 0\\.003572509259601702\ \(0\)\
\-\ likely\\:\\ 0\\.003560251057512048\ \(0\)\
\-\ she\\:\\ 0\\.0035432587022956757\ \(0\)\
\-\ include\\:\\ 0\\.003540847101964973\ \(0\)\
\-\ secondary\\:\\ 0\\.0035288478087279287\ \(0\)\
\-\ however\\:\\ 0\\.003514576153023738\ \(0\)\
\-\ trauma\\:\\ 0\\.0034520070631579454\ \(0\)\
\-\ been\\:\\ 0\\.0034339658633146105\ \(0\)\
\-\ lobe\\:\\ 0\\.003396344679355294\ \(0\)\
\-\ significant\\:\\ 0\\.0033941612275542443\ \(0\)\
\-\ enhancement\\:\\ 0\\.003383292121304337\ \(0\)\
\-\ lesions\\:\\ 0\\.003378966774511001\ \(0\)\
\-\ signal\\:\\ 0\\.0033280270757352717\ \(0\)\
\-\ than\\:\\ 0\\.0033073099777227092\ \(0\)\
\-\ patients\\:\\ 0\\.0032667276209247063\ \(0\)\
\-\ anterior\\:\\ 0\\.0032508018076259047\ \(0\)\
\-\ \\(\\:\\ 0\\.003201012080844286\ \(0\)\
\-\ \\)\\:\\ 0\\.00316191000936472\ \(0\)\
\-\ symptoms\\:\\ 0\\.0031457274400267937\ \(0\)\
\-\ bone\\:\\ 0\\.0031365357185522452\ \(0\)\
\-\ physical\\:\\ 0\\.003096758153000352\ \(0\)\
\-\ into\\:\\ 0\\.0030034362894530383\ \(0\)\
\-\ 1\\:\\ 0\\.0030034362894530383\ \(0\)\
\-\ \\;\\:\\ 0\\.0029917595102697103\ \(0\)\
\-\ noted\\:\\ 0\\.0029917595102697103\ \(0\)\
\-\ associated\\:\\ 0\\.0029785266793319084\ \(0\)\
\-\ without\\:\\ 0\\.0029719544554773418\ \(0\)\
\-\ imaging\\:\\ 0\\.002957273005104288\ \(0\)\
\-\ of\\:\\ 0\\.0029255016448534762\ \(0\)\
\-\ other\\:\\ 0\\.0029093627011853008\ \(0\)\
\-\ small\\:\\ 0\\.0029077921482734397\ \(0\)\
\-\ case\\:\\ 0\\.0027614541105868105\ \(0\)\
\-\ demonstrates\\:\\ 0\\.002757195275706331\ \(0\)\
\-\ lateral\\:\\ 0\\.00272772237167585\ \(0\)\
\-\ 2\\:\\ 0\\.002718027321285888\ \(0\)\
\-\ findings\\:\\ 0\\.0026866129036779316\ \(0\)\
\-\ multiple\\:\\ 0\\.002658502220796557\ \(0\)\
\-\ old\\:\\ 0\\.0025847403156935146\ \(0\)\
\-\ lesion\\:\\ 0\\.00257098260856788\ \(0\)\
\-\ patient\\:\\ 0\\.0025305522331355627\ \(0\)\
\-\ seen\\:\\ 0\\.0024942800813407538\ \(0\)\
\-\ that\\:\\ 0\\.0021801783287427228\ \(0\)\
\-\ there\\:\\ 0\\.0018784572473633512\ \(0\)\
\-\ ct\\:\\ 0\\.0017655888528686013\ \(0\)\
\-\ \\.\\:\\ 0\\.0016779692099188788\ \(0\)\
\-\ pain\\:\\ 0\\.0015415187112713955\ \(0\)\
\-\ or\\:\\ 0\\.001479354134362936\ \(0\)\
\-\ left\\:\\ 0\\.0014122677537266098\ \(0\)\
\-\ year\\:\\ 0\\.0014122677537266098\ \(0\)\
\-\ with\\:\\ 0\\.0013826195106633942\ \(0\)\
